Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity

Vorolanib (CM082) is a multi-targeted tyrosine kinase receptor inhibitor with a short half-life and limited tissue accumulation that has been shown to reduce choroidal neovascularization in rats. In this preclinical study, vorolanib demonstrated competitive binding and inhibitory activities with KDR...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Chris, Yuan, Xiaobin, Shen, Zhilin, Wang, Yang, Ding, Lieming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861424/
https://www.ncbi.nlm.nih.gov/pubmed/35252556
http://dx.doi.org/10.1016/j.omto.2022.01.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861424/
https://www.ncbi.nlm.nih.gov/pubmed/35252556
http://dx.doi.org/10.1016/j.omto.2022.01.001

Ejemplares similares